These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37258312)

  • 61. [Short-term outcomes and prognosis of palliative surgery for malignant bowel obstruction caused by peritoneal metastasis of colorectal cancer].
    Chen PJ; Wang L; Chen N; Lu XY; Wang HS; He X; Wang Z; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Nov; 22(11):1051-1057. PubMed ID: 31770836
    [No Abstract]   [Full Text] [Related]  

  • 62. Association of a Prophylactic Surgical Approach to Stage IV Small Intestinal Neuroendocrine Tumors With Survival.
    Daskalakis K; Karakatsanis A; Hessman O; Stuart HC; Welin S; Tiensuu Janson E; Öberg K; Hellman P; Norlén O; Stålberg P
    JAMA Oncol; 2018 Feb; 4(2):183-189. PubMed ID: 29049611
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Examining Perioperative Risk Associated with Simultaneous Resection of Primary Neuroendocrine Tumors and Synchronous Hepatic Metastases.
    Heidenreich BM; Kemp Bohan PM; Flor RJ; Bader JO; Vreeland TJ; O'Connor VV; Nelson DW
    World J Surg; 2021 Feb; 45(2):531-542. PubMed ID: 33151372
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prognostic role of bowel involvement in optimally cytoreduced advanced ovarian cancer: a retrospective study.
    Giorda G; Gadducci A; Lucia E; Sorio R; Bounous VE; Sopracordevole F; Tinelli A; Baldassarre G; Campagnutta E
    J Ovarian Res; 2014 Jul; 7():72. PubMed ID: 25328074
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-Free Survival and Overall Survival.
    Chen JX; Rose S; White SB; El-Haddad G; Fidelman N; Yarmohammadi H; Hwang W; Sze DY; Kothary N; Stashek K; Wileyto EP; Salem R; Metz DC; Soulen MC
    Cardiovasc Intervent Radiol; 2017 Jan; 40(1):69-80. PubMed ID: 27738818
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection.
    Kimbrough CW; Beal EW; Dillhoff ME; Schmidt CR; Pawlik TM; Lopez-Aguiar AG; Poultsides G; Makris E; Rocha FG; Crown A; Abbott DE; Fisher AV; Fields RC; Krasnick BA; Idrees K; Marincola-Smith P; Cho CS; Beems M; Maithel SK; Cloyd JM
    Surgery; 2019 Mar; 165(3):657-663. PubMed ID: 30377003
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Success rate and safety of tumor debulking with diaphragmatic surgery for advanced epithelial ovarian cancer and peritoneal cancer.
    Saitou M; Iida Y; Komazaki H; Narui C; Matsuno K; Kawabata A; Ueda K; Tanabe H; Takakura S; Isonishi S; Sasaki H; Okamoto A
    Arch Gynecol Obstet; 2015 Mar; 291(3):641-6. PubMed ID: 25182215
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
    Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
    Am J Obstet Gynecol; 2019 Oct; 221(4):326.e1-326.e7. PubMed ID: 31082382
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Safety and efficacy of transarterial embolization combined with octreotide LAR on reducing tumor burden for neuroendocrine tumor liver metastasis].
    Liu YM; Lian F; Zhou XF; Chen WC; Liu HK; Yao W; Fan WZ; Li JP; Chen J; Wang Y
    Zhonghua Yi Xue Za Zhi; 2019 Apr; 99(15):1142-1146. PubMed ID: 31006216
    [No Abstract]   [Full Text] [Related]  

  • 70. Comparing Laparotomy with Robot-assisted Interval Debulking Surgery for Patients with Advanced Epithelial Ovarian Cancer Receiving Neoadjuvant Chemotherapy.
    Zhang Y; Grant MS; Zhang X; Paraghamian SE; Tan X; Clark LH
    J Minim Invasive Gynecol; 2021 Jun; 28(6):1237-1243. PubMed ID: 33248314
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Impact of treatment modality on overall survival in women with advanced endometrial cancer: A National Cancer Database analysis.
    Chambers LM; Jia X; Rose PG; AlHilli M
    Gynecol Oncol; 2021 Feb; 160(2):405-412. PubMed ID: 33221023
    [TBL] [Abstract][Full Text] [Related]  

  • 72. PROGNOSTIC FACTORS FOR SURVIVAL OF MEN1 PATIENTS WITH DUODENOPANCREATIC TUMORS METASTATIC TO THE LIVER: RESULTS FROM THE DMSG.
    Conemans EB; Nell S; Pieterman CRC; de Herder WW; Dekkers OM; Hermus AR; van der Horst-Schrivers AN; Bisschop PH; Havekes B; Drent ML; Vriens MR; Valk GD
    Endocr Pract; 2017 Jun; 23(6):641-648. PubMed ID: 28225311
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver Metastases.
    Cloyd JM; Omichi K; Mizuno T; Kawaguchi Y; Tzeng CD; Conrad C; Chun YS; Aloia TA; Katz MHG; Lee JE; Halperin D; Yao J; Vauthey JN; Dasari A
    Ann Surg Oncol; 2018 Jun; 25(6):1709-1715. PubMed ID: 29626307
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience.
    Rose DM; Essner R; Hughes TM; Tang PC; Bilchik A; Wanek LA; Thompson JF; Morton DL
    Arch Surg; 2001 Aug; 136(8):950-5. PubMed ID: 11485537
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Second primary cancers and survival among neuroendocrine tumor patients.
    Bateni SB; Coburn NG; Law C; Singh S; Myrehaug S; Assal A; Hallet J
    Endocr Relat Cancer; 2023 Aug; 30(8):. PubMed ID: 37184947
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Delays from neoadjuvant chemotherapy to interval debulking surgery and survival in ovarian cancer.
    Liu YL; Zhou QC; Iasonos A; Filippova OT; Chi DS; Zivanovic O; Sonoda Y; Gardner G; Broach V; OCearbhaill R; Konner JA; Aghajanian CA; Long K; Tew W
    Int J Gynecol Cancer; 2020 Oct; 30(10):1554-1561. PubMed ID: 32522770
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?
    Sioulas VD; Schiavone MB; Kadouri D; Zivanovic O; Roche KL; O'Cearbhaill R; Abu-Rustum NR; Levine DA; Sonoda Y; Gardner GJ; Leitao MM; Chi DS
    Gynecol Oncol; 2017 Apr; 145(1):15-20. PubMed ID: 28238354
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Similar Overall Survival Using Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients Aged Over 75 Years with High-Grade Ovarian Cancer.
    Piedimonte S; Kessous R; Laskov I; Abitbol J; Kogan L; Yasmeen A; Salvador S; Lau S; Gotlieb WH
    J Obstet Gynaecol Can; 2020 Nov; 42(11):1339-1345. PubMed ID: 32859533
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].
    Wang DF; Zhang GN; Peng CR; Shi Y; Shi XW
    Zhonghua Fu Chan Ke Za Zhi; 2021 Jun; 56(6):385-392. PubMed ID: 34154313
    [No Abstract]   [Full Text] [Related]  

  • 80. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival.
    Sarmiento JM; Heywood G; Rubin J; Ilstrup DM; Nagorney DM; Que FG
    J Am Coll Surg; 2003 Jul; 197(1):29-37. PubMed ID: 12831921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.